Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

Share Price is delayed by 15 minutes
Get Live Data
0.35    0.00 (0.00%)
Bid:
0.30
Ask:
0.40
Spread: 0.10 (33.333%)
Market Cap: £8.01m
VRCI Live PriceLast checked at - London Stock Exchange

Intraday Verici Dx Share Chart

Holding(s) in Company

25 Jul 2025 13:05

RNS Number : 6531S
Verici Dx PLC
25 July 2025
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BM8HZD43

Issuer Name

VERICI DX PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting rights

3. Details of person subject to the notification obligation

Name

Octopus Investments Limited

City of registered office (if applicable)

London

Country of registered office (if applicable)

England

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

24-Jul-2025

6. Date on which Issuer notified

25-Jul-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

1.510000

0.000000

1.510000

21479825

Position of previous notification (if applicable)

8.920000

0.000000

8.920000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BM8HZD43

21479825

1.510000

Sub Total 8.A

21479825

1.510000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Octopus Capital Limited

Octopus Investments Limited

1.510000

1.510000%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

25/07/2025

13. Place Of Completion

33 Holborn, London, EC1N 2HT

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFIFDVIEFIE
Date   Source Headline
6th Jul 20267:00 amRNS-RInvestor presentation
1st Jul 202611:22 amRNSHolding(s) in Company
29th Jun 20267:00 amRNSFinal results for the year ended 31 December 2025
25th Jun 20264:08 pmRNSHolding(s) in Company
24th Jun 20265:24 pmRNSHolding(s) in Company
24th Jun 20264:34 pmRNSHolding(s) in Company
24th Jun 202612:37 pmRNSHolding(s) in Company
24th Jun 202611:13 amRNSHolding(s) in Company
24th Jun 20269:06 amRNSHolding(s) in Company
24th Jun 20267:00 amRNSNew York State clinical lab certification received
23rd Jun 20264:08 pmRNSHolding(s) in Company
22nd Jun 20263:15 pmRNSResult of General Meeting
19th Jun 20263:11 pmRNSHolding(s) in Company
12th Jun 20267:00 amRNSResult of WRAP Retail Offer
8th Jun 20261:52 pmRNSPublication of Circular & Notice of GM
8th Jun 20267:00 amRNSWRAP Retail Offer for up to £200,000
5th Jun 20265:41 pmRNSResult of Placing & raising gross proceeds c£2.5m
5th Jun 202611:40 amRNSProposed Fundraising via Placing
4th Jun 20263:40 pmRNSHolding(s) in Company
2nd Jun 202612:41 pmRNSHolding(s) in Company
2nd Jun 20267:00 amRNSAMA grants additional CPT® Code for ProtegaTM
2nd Jun 20267:00 amRNS-RStudy validating economic advantages of PTRA test
27th May 20264:04 pmRNSHolding(s) in Company
22nd May 20263:53 pmRNSHolding(s) in Company
19th May 20267:00 amRNSClinical study validating PTRA test published
13th May 20264:06 pmRNSHolding(s) in Company
11th May 20262:31 pmRNSHolding(s) in Company
11th May 202611:23 amRNSHolding(s) in Company
30th Apr 20264:30 pmRNSHolding(s) in Company
24th Apr 20265:19 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSPositive Q1 Trading Update
10th Apr 20263:24 pmRNSHolding(s) in Company
7th Apr 20265:20 pmRNSHolding(s) in Company
31st Mar 20267:00 amRNSBoard Change
5th Feb 20267:01 amRNSFY25 Trading Update
5th Feb 20267:00 amRNSAgreement with BCBS of Illinois for Tutivia™
12th Nov 20257:00 amRNS-RCompletion of CAP accreditation audit
6th Nov 20257:00 amRNSProvider Participation Agreement with Prime Health
3rd Nov 20257:00 amRNS-RCompletion of ISO 27001 surveillance audit
30th Oct 20257:00 amRNSOptions revision & Grant of new share options
6th Oct 20257:01 amRNSBoard Changes
6th Oct 20257:00 amRNSUpdate on Tutivia™ test adoption
1st Oct 20254:55 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
1st Aug 202510:40 amRNSHolding(s) in Company
31st Jul 20255:33 pmRNSHolding(s) in Company
31st Jul 20255:28 pmRNSHolding(s) in Company
31st Jul 20253:24 pmRNSHolding(s) in Company
31st Jul 20257:00 amRNSTutivia™ abstracts for World Transplant Congress
30th Jul 20252:32 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.